Sep 08, 2021
In the new fast-paced world, with unlimited access to information and technology, it gets overwhelming for various companies, be it an established goliath or a new start-up, to take important decisions. It often leads to confusion and dilemmas causing delays in operations, financial losses, fiscal deficits, and oth...
Read More...
Jul 17, 2018
Alkermes Gets FDA approval for Aristada Initio (aripiprazole lauroxil) as Part of Schizophrenia Treatment Combination Alkermes has announced that the U.S. FDA approved ARISTADA INITIO (aripiprazole lauroxil) for the initiation of ARISTADA (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic f...
Read More...
Feb 06, 2018
Charles River to fuel hit discovery with AstraZeneca high-throughput collaboration After collaborating with AstraZeneca Charles River is now looking forward to strengthening its high-throughput screening capabilities (HTC) with the help of highly advance AstraZeneca technology. Now the company is able to offer the ...
Read More...
Nov 29, 2017
Gender matters for Party drug Ketamine to work its anti-depressant activity in mice Experiments involving the popular party drug ketamine, a psychoactive recreational drug used to uplift mood of the user, in mice has deepened the mystery of how the dug affects the brain further. Results of a study conducted at the U...
Read More...
Nov 28, 2017
Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Mi...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper